Inclusion Criteria:

- Cutaneous warts on ingers and/or palms and/or toes and/or soles of feet

- Common warts and mosaic warts, diagnosed by an experienced dermatologist

- Solitary wart lesions or 2 or more lesions per patient

- Lesions present for more than 6 months

- Men or women, aged 18 or above

- History of kidney transplantation and immune suppressive therapy after transplant

- Concomitant immune suppressive therapy stable for 6 months prior to randomization

- Agreement from patient to allow photographs to be taken and used as part of trial
data documentation (2 centres)

- Women of childbearing potential must have negative pregnancy test at screening and
must use adequate contraception

- Ability to comply with requirements of trial

- Written informed consent

Exclusion Criteria:

- Verruca plana lesions

- Suspected allergy to milk verified by serum analysis of IgE towards cow milk

- Breastfeeding

- Any local medication for any purpose other than wart treatment in target area during
4 weeks prior to randomization and during treatment period

- Concomitant treatment with other wart therapies two weeks prior to randomization and
during trial period

- Intolerance towards bovine alpha-lactalbumin, oleic acid or any excipient in the
formulation

- Known HIV infection or any current uncontrolled infection

- Any chronic or acute skin condition susceptible of interfering with evaluation of
drug effect in this trial

- Participation in any investigational trial or use of any investigational drug within
30 days prior to inclusion in this trial

- Any health problems which according to Investigator's clinical judgment will make the
patient unsuitable for inclusion in the trial